Please login to the form below
ICOs
This page shows the latest ICOs news and features for those working in and with pharma, biotech and healthcare.
Celgene cuts back Jounce alliance ahead of BMS merger
Jounce now takes back full worldwide rights to the rest of its pipeline, including the ICOS-targeting vopratelimab, PD-1 inhibitor JTZ-4014 and all discovery programmes. ... BMS has its own anti-ICOS agonist, BMS-986226, in clinical trials and the
Latest news
-
Wilmington Healthcare enhances digital platform, McCann recognised at IPA Effectiveness Awards
Courses on offer include What you need to know about NHS England's plan for ICSs and ICOs, which addresses how integrated care systems and integrated care organisations will start to
-
The NHS at 70: celebrations, renewed reforms and difficult choices
Key to the future of the health service in England will be the Integrated Care Organisations (ICOs), which aim to bring together health and social care services, both to improve patient ... At the moment there are 12m people in England covered by ICOs
-
Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS
the lack of a legal framework is hampering the ICOs from making faster progress. ... Secondly, there has been considerable resistance against the changes, with campaigners claiming ICOs/ACSs are another backdoor privatisation of the NHS.
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this month, as well as Celldex’ anti-CD27 agonist
-
Immuno-oncology at ASCO: survival data, combinations and new indications
Standout examples of that this year include Jounce Therapeutics - which fell dramatically after data from a phase I trial of its ICOS agonist antibody JTX-2011 alongside Bristol-Myers Squibb’s
More from news
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Happy 70th birthday NHS: the next 70 need to be very different
Key to the future of the health service in England will be the Integrated Care Organisations (ICOs), which aim to bring together health and social care services, both to improve patient ... At the moment there are 12 million people in England covered by
-
30 Women Leaders in UK Healthcare (part 3)
ICOs (formerly known as Accountable Care Systems) require exceptional individuals who can break down the many institutional, cultural and financial barriers between hospitals, primary care and local authorities.
-
Deal Watch July 2016
It is a humanised inducible co-stimulator (ICOS) agonist antibody, designed to both stimulate T effector cells and selectively reduce intra-tumoural T regulatory cells.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Wilmington Healthcare adds innovative new features to its digital learning platform for pharma and medtech
New courses on offer include: “What do you need to know about NHS England's plan for ICSs and ICOs?”, which addresses how integrated care systems and integrated care organisations will
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
- UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Pegasus
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
